Fig. 2

Overall survival in CD8⁺ T-cell and Mφ gene signature-defined subgroups. A–B Kaplan–Meier overall survival analysis in four subgroups defined by CD8⁺ T-cell signature and Mφ signature in (A) tislelizumab-treated GEP BEP and (B) TCGA pan-solid tumor dataset. Median overall survival was estimated by the Kaplan–Meier method and the log-rank test was used to compare survival curves between defined biomarker subgroups. BEP, biomarker-evaluable population; CI, confidence interval; GEP, gene expression profiling; Mφ, macrophages; TCGA, The Cancer Genome Atlas